The Trifecta valve with Glide Technology (GT) is intended as a replacement for a diseased, damaged, or malfunctioning native or prosthetic aortic heart valve.
Surgical aortic valve replacement (SAVR)—for example, with the Trifecta valve—is the gold standard for the treatment of aortic stenosis.1
If symptomatic patients with aortic valve stenosis—who are already on medical therapy—do not undergo aortic valve replacement, mortality rates are approximately 25% at 1 year and 50% at 2 years. Aortic valve replacement is the only definitive treatment for such patients.2
When selecting a SAVR valve, physicians are encouraged to consider:
- Hemodynamic performance
- Rate of prosthetic-patient mismatch
AP2947045-WBO Rev. A
- Bonow RO, et al. Management strategies and future challenges for aortic valve disease. Lancet. 2016;387:1312–1323.
- Ren X. Aortic stenosis. MedScape. emedicine.medscape.com/article/150638-overview. Published March 23, 2017.